Search

Displaying results 2541 - 2550 of 10000 in total
  1. Drug

    Sulconazole

    go.drugbank.com/drugs/DB06820
    Approved

    Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis … [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial fungal infections.[A255612]

  2. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    It has one chiral center and is the R-stereoisomer.[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … [A274581] On December 19, 2025, the U.S. FDA approved nerandomilast tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults.

  3. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal. … [A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338]

  4. Drug

    Boceprevir

    go.drugbank.com/drugs/DB08873
    ApprovedWithdrawn

    with [DB00811], [DB00008], and [DB00022] as first line therapy for Hepatitis C [A19593]. … Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance.

    Products: VICTRELIS ® CAPSULAS 200 MG (MOLECULA PROTEGIDA)
  5. Drug

    Alcloxa

    go.drugbank.com/drugs/DB11205
    Approved

    Mixtures: Watkins Roll On Deodorant, Medi Peel Herbpirin Salt Toothpas Te
  6. Drug

    Equine Botulinum Neurotoxin G Immune FAB2

    go.drugbank.com/drugs/DB13899
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.

  7. Drug

    Equine Botulinum Neurotoxin D Immune FAB2

    go.drugbank.com/drugs/DB13902
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.

  8. Drug

    alpha-Linolenic acid

    go.drugbank.com/drugs/DB00132
    ApprovedInvestigationalNutraceuticalWithdrawn

    It is a component of many common vegetable oils and is important to human nutrition.

    Mixtures: PRIM E CAPSULE, Huile D'onagre Vitamin E
  9. Drug

    Sebetralstat

    go.drugbank.com/drugs/DB18305
    ApprovedInvestigational

    Food and Drug Administration approved sebetralstat on July 7, 2025, for treating acute HAE attacks in patients aged 12 years and older [L53533, L53538]. … This plasma kallikrein inhibitor works by reducing bradykinin, the substance that causes the characteristic swelling in HAE attacks [L53533]. The U.S.

    Synonyms: 1H-Pyrazole-4-carboxamide, N-[(3-fluoro-4-methoxy-2-pyridinyl)methyl]-3-methoxymethyl)-1-[[4-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]methyl]-, N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1(2H)-yl)methyl]phenyl}methyl)-1H-pyrazol-4-carboxamideCategories: Drugs Used in Hereditary Angioedema
  10. Drug

    Equine Botulinum Neurotoxin F Immune FAB2

    go.drugbank.com/drugs/DB13901
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients.